ImmuPharma PLC (IMM)

7.86
+0.29(+3.76%)
  • Volume:
    165,916
  • Bid/Ask:
    7.70/7.98
  • Day's Range:
    7.42 - 8.00

IMM Overview

Prev. Close
7.71
Day's Range
7.42-8
Revenue
120K
Open
7.42
52 wk Range
7-14.75
EPS
-0.03
Volume
165,916
Market Cap
19.29M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
557,438
P/E Ratio
-
Beta
1.24
1-Year Change
-35.07%
Shares Outstanding
250,221,297
Next Earnings Date
28 Sept 2021
What is your sentiment on ImmuPharma PLC?
or
Vote to see community's results!

ImmuPharma PLC News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyNeutralStrong Sell
Technical IndicatorsStrong BuyStrong BuyStrong BuySellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyNeutralStrong Sell

ImmuPharma PLC Company Profile

ImmuPharma PLC Company Profile

Sector
Services
Employees
18

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.

Read More
  • Added some more at this crazy price, its now my biggest holding in the portfolio.
    0
    • “The strengthened balance sheet position following the £6.5m placing in September 2020, provides a cash runway to end 2023. Lupus being an attractive market and poorly met medical need, Dr Malik believes the shares are oversold and reiterate their BUY rating and TP of 100p.”
      1
      • dr malik joking right? tp 100p give the company a market cap of 250M! tell me would u buy a company for 250m with 10m on the balance sheet?
        1
    • This report is worth readinghttps://thelifesciencesdivision.com/research/portal/?#/portal/the-life-sciences-division/research/c84d1aa9-f672-42fb-a774-ab7fe84a3a99/referrer/GB0033711010
      1
      • Looks like this has finally bottomed. I have built a substantial size position and expect to see it be 20p at least in a few months
        0
        • I had this at 9.16 unfortunately.
          0
          • its a time to load up ,in the stochastic over sold zone,just needs a bit of volume ,will move up very quickly
            0
            • Now its the time to buy. RNS looks neutural, just slight delay
              0
              • One of the top shareholders sold a big chunk on the last day of 2020....not a good sign
                0
                • This share is dead
                  0
                  • this gone more then double soon as the new drugs approved
                    1
                    • Bargain of the year, the potential for this is huge. Easily 100% gain before xmas
                      0
                      • can see investers are lining up
                        0
                    • shorts are closing, this is going to rally back now
                      1
                      • time to buy
                        1
                        • this share is doing taxi.....nearly taking off....good time to buy....fill the boots to avoid buying expensive.......
                          0
                          • Lets hope so
                            2
                            • I’d be happy with £5
                              2
                              • It’s now or never. I believe this will be £5 by next week.
                                3
                                • Fluffed it.  Theres been a nasty drop today.
                                  0
                                • Lol
                                  0
                              • Lincese deal coming up soon. £5 on the cards
                                3
                                • Share price to increase by 100%.
                                  1
                                  • Support your view with some facts / analysis
                                    0
                                  • It did and you missed the boat.
                                    0
                                Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.